Literature DB >> 16625245

The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles.

T Kottke1, J Qiao, R M Diaz, A Ahmed, B Vroman, J Thompson, L Sanchez-Perez, R Vile.   

Abstract

We have reported that retroviral particles adhered to the surface of antigen-specific T cells can be carried to metastases following adoptive transfer in vivo, a process we have called viral hitch hiking. Following antigen-driven T-cell accumulation at tumors, viral particles productively infect tumor cells via envelope/receptor dependent interactions ('hand on' of virus from the T cell to the tumor cell). We describe here a second envelope/receptor independent pathway of viral hand on from T cells, dependent on T-cell activation. We show that the endosomolytic property of perforin promotes release of viral particles from endosomes into which they are co-delivered along with cytotoxic granules from the activated T cell. Therefore, hand on of MLV particles lacking any envelope can be used for in vivo delivery of vectors, where targeting is at the extremely specific level of recognition of antigen by the T-cell receptor, thereby dispensing with the need to engineer viral envelopes. These data reveal a novel pathway by which MLV viral particles exploit a functional immunological synapse and present new opportunities both to improve the efficacy of adoptive T-cell transfer and to target vectors for systemic gene delivery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16625245     DOI: 10.1038/sj.gt.3302722

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  6 in total

1.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

Review 2.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

3.  Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Authors:  J Qiao; H Wang; T Kottke; R M Diaz; C Willmon; A Hudacek; J Thompson; K Parato; J Bell; J Naik; J Chester; P Selby; K Harrington; A Melcher; R G Vile
Journal:  Gene Ther       Date:  2008-02-28       Impact factor: 5.250

Review 4.  Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies.

Authors:  Christos Dogrammatzis; Hope Waisner; Maria Kalamvoki
Journal:  Front Cell Dev Biol       Date:  2020-05-26

5.  Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.

Authors:  Sadia Zafar; Dafne Carolina Alves Quixabeira; Tatiana Viktorovna Kudling; Victor Cervera-Carrascon; Joao Manuel Santos; Susanna Grönberg-Vähä-Koskela; Fang Zhao; Pasi Aronen; Camilla Heiniö; Riikka Havunen; Suvi Sorsa; Anna Kanerva; Akseli Hemminki
Journal:  Cancer Gene Ther       Date:  2020-09-12       Impact factor: 5.987

Review 6.  Cell carriers for oncolytic viruses: current challenges and future directions.

Authors:  Dominic G Roy; John C Bell
Journal:  Oncolytic Virother       Date:  2013-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.